We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie/Boehringer Report Crohn's Disease Drug Interim Data
Read MoreHide Full Article
AbbVie Inc. (ABBV - Free Report) and Boehringer Ingelheim announced that interim results were presented from a randomized, placebo-controlled, proof-of-concept phase II study evaluating intravenous risankizumab (IL-23 inhibitor; 200 mg and 600 mg) versus placebo administered at weeks zero, four, and eight in patients with moderately to severely active Crohn's disease. Data were presented at the Digestive Disease Week.
Results showed that 24% and 37% of patients achieved clinical remission with 200 mg and 600 mg risankizumab, respectively, compared with the placebo arm (15%) after 12 weeks. Additionally, endoscopic remission was achieved by 15% and 20% of patients who received 200 mg and 600 mg risankizumab, respectively, compared with 3% of patients who received placebo. Moreover, almost twice as many patients achieved a clinical response with risankizumab (37% and 42% in the 200 mg and 600 mg groups, respectively), compared with the placebo group (21%) at week 12.
On the safety front, risankizumab was found to be well tolerated in the study with numerically fewer severe or serious adverse events being reported in patients when treated with risankizumab compared to placebo.
Considering that patients with moderate-to-severe Crohn's disease who have failed anti-TNF therapy have inadequate choices for treatment, the interim data are encouraging. The study is currently in progress and will evaluate patients up to 52 weeks.
In Mar 2016, AbbVie and Boehringer had announced a collaboration agreement under which the former is responsible for the development and commercialization of risankizumab globally. Apart from Crohn’s disease, risankizumab is also being evaluated for a couple of other immunological disorders including psoriasis and psoriatic arthritis.
Upon successful development and subsequent approval, risankizumab will enter a high potential but immensely crowded market given the presence of drugs like Stelara, Cosentyx and Enbrel among others.
AbbVie is currently a Zacks Rank #5 (Strong Sell) stock. Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Retrophin, Inc. , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AbbVie/Boehringer Report Crohn's Disease Drug Interim Data
AbbVie Inc. (ABBV - Free Report) and Boehringer Ingelheim announced that interim results were presented from a randomized, placebo-controlled, proof-of-concept phase II study evaluating intravenous risankizumab (IL-23 inhibitor; 200 mg and 600 mg) versus placebo administered at weeks zero, four, and eight in patients with moderately to severely active Crohn's disease. Data were presented at the Digestive Disease Week.
Results showed that 24% and 37% of patients achieved clinical remission with 200 mg and 600 mg risankizumab, respectively, compared with the placebo arm (15%) after 12 weeks. Additionally, endoscopic remission was achieved by 15% and 20% of patients who received 200 mg and 600 mg risankizumab, respectively, compared with 3% of patients who received placebo. Moreover, almost twice as many patients achieved a clinical response with risankizumab (37% and 42% in the 200 mg and 600 mg groups, respectively), compared with the placebo group (21%) at week 12.
On the safety front, risankizumab was found to be well tolerated in the study with numerically fewer severe or serious adverse events being reported in patients when treated with risankizumab compared to placebo.
Considering that patients with moderate-to-severe Crohn's disease who have failed anti-TNF therapy have inadequate choices for treatment, the interim data are encouraging. The study is currently in progress and will evaluate patients up to 52 weeks.
In Mar 2016, AbbVie and Boehringer had announced a collaboration agreement under which the former is responsible for the development and commercialization of risankizumab globally. Apart from Crohn’s disease, risankizumab is also being evaluated for a couple of other immunological disorders including psoriasis and psoriatic arthritis.
Upon successful development and subsequent approval, risankizumab will enter a high potential but immensely crowded market given the presence of drugs like Stelara, Cosentyx and Enbrel among others.
AbbVie is currently a Zacks Rank #5 (Strong Sell) stock. Some better-ranked stocks in the health care sector include Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Retrophin, Inc. , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>